CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Cash Flows [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (548)	$ (118)	$ (352)
Adjustments to reconcile net loss to cash provided by operating activities:
Depreciation, amortization and impairments	554	647	690
Change in deferred income taxes	(22)	(21)	(33)
Stock-based compensation	61	37	44
Noncash Interest Expense	22	25	25
Earnings from equity investments, net	6	(24)	(25)
Distributed earnings from equity investments	22	26	33
Inventory Write-down	110	15	29
Loss (gain) on sale of assets and other, net	0	6	(16)
Loss on debt financing transactions	1	100	93
Loss (gain) on remeasurement of debt	51	(9)	(43)
Contingent acquisition consideration fair value adjustment	0	2	29
Changes in assets and liabilities, net of effects of acquisitions:
Receivables, net(1)	121	(61)	23
Inventories(1)	14	(29)	2
Other assets and liabilities	(35)	(31)	(27)
Accounts payable and accrued liabilities(1)	60	(19)	(126)
Net cash provided by operating activities	471	546	346
Cash flows from investing activities:
Payments to Acquire Other Productive Assets	190	285
Capital expenditures			(391)
Acquisitions of businesses and assets, net of cash acquired	(13)	0	(297)
Acquisitions and additions to equity method investments	(6)	(1)	(180)
Distributions of capital from equity investments	12	23	30
Proceeds from asset sales and other	24	0	40
Net cash used in investing activities	(173)	(263)	(798)
Cash flows from financing activities:
Borrowings under SGI revolving credit facility	530	270	560
Repayments under SGI revolving credit facility	(190)	(400)	(585)
Proceeds from issuance of notes and term loans	550	2,300	2,512
Repayment of assumed NYX and other acquisitions debt	0	0	(290)
Payments on long-term debt	(42)	(44)	(39)
Repayments of notes and term loans (including redemption premium)	(341)	(2,523)	(2,210)
Payments of debt issuance and deferred financing costs	(10)	(35)	(38)
Payments on license obligations	(36)	(40)	(45)
Proceeds From Sale Of Finance Receivables, Financing Activities	0	11	0
Net proceeds from the sale of SciPlay common stock	0	342	0
Payments of deferred SciPlay common stock offering costs	0	(9)	0
Net redemptions of common stock under stock-based compensation plans and other	2	(1)	(21)
Net cash provided by (used in) financing activities	463	(129)	(156)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	7	1	(6)
Increase (decrease) in cash, cash equivalents and restricted cash	768	155	(614)
Cash, cash equivalents and restricted cash, beginning of period	375	220	834
Cash, cash equivalents and restricted cash, end of period	1,143	375	220
Supplemental cash flow information:
Cash paid for interest	471	549	633
Income taxes paid	22	41	33
Payment for Contingent Consideration Liability, Operating Activities	4	26	0
Non-cash investing and financing transactions:
Note Rollover	0	0	3,275
Non-cash additions to intangible assets related to license agreements	0	0	138
NYX non-cash consideration transferred (including 2017 acquisition of ordinary shares)	0	0	93
Goodwill, Impairment Loss	$ 54	$ 0	$ 0